A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study

Purpose. To assess the safety profile of ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration (nAMD) in routine clinical practice. Methods. This 2-year, multicentre, observational study was conducted to capture real-world early practice and outcomes across Europe, shortly...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagliarini, Sergio, Beatty, Stephen, Lipkova, Blandina, Perez-Salvador Garcia, Eduardo, Reynders, Stefaan, Gekkieva, Margarita, Si Bouazza, Abdelkader, Pilz, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020221/
https://www.ncbi.nlm.nih.gov/pubmed/24868458
http://dx.doi.org/10.1155/2014/857148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020221/
https://www.ncbi.nlm.nih.gov/pubmed/24868458
http://dx.doi.org/10.1155/2014/857148

Ejemplares similares